GABAergic Inhibitory Neurons as Therapeutic Targets for Cognitive Impairment in Schizophrenia

Acta Pharmacologica Sinica - United Kingdom
doi 10.1038/aps.2017.172
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Springer Science and Business Media LLC

Related search

Cognitive Impairment as a Diagnostic Criterion and Treatment Target in Schizophrenia

World Psychiatry
PsychiatryMental HealthPsychiatric Mental Health
2019English

Neural Correlates of Cognitive Impairment in Schizophrenia

British Journal of Psychiatry
MedicinePsychiatryMental Health
2011English

Why Are There No Approved Treatments for Cognitive Impairment in Schizophrenia?

World Psychiatry
PsychiatryMental HealthPsychiatric Mental Health
2019English

Signaling Pathways in Schizophrenia: Emerging Targets and Therapeutic Strategies

Trends in Pharmacological Sciences
ToxicologyPharmacology
2010English

GABAergic Signaling as Therapeutic Target for Autism Spectrum Disorders

Frontiers in Pediatrics
Child HealthPediatricsPerinatology
2014English

Cognitive-Behavioural Therapy for Schizophrenia: Filling the Therapeutic Vacuum

British Journal of Psychiatry
MedicinePsychiatryMental Health
2003English

Bromodomains as Therapeutic Targets

Expert Reviews in Molecular Medicine
Molecular MedicineMolecular Biology
2011English

Cognitive Impairment and Psychosis in Schizophrenia: Independent or Linked Conditions?

World Psychiatry
PsychiatryMental HealthPsychiatric Mental Health
2019English

Micro-RNP as Therapeutic Targets for Neuroblastomas

Innovative medicine of Kuban
2019English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy